Achieve Life Sciences Secures US Manufacturing for Cytisinicline Ahead of June 23 PDUFA
Achieve Life Sciences secured a US manufacturing partnership with Adair Pharma after an FDA inspection flagged its international supplier, ensuring supply chain readiness for Cytisinicline before PDUFA on June 23, 2026. It plans a first-half 2027 launch with over three years of stockpiled raw materials and 40 payer engagements.
1. NDA Submission and PDUFA Timeline
Achieve Life Sciences submitted a New Drug Application for Cytisinicline targeting the first new FDA-approved smoking cessation treatment in two decades, with a PDUFA date set for June 23, 2026 and a planned commercial launch in the first half of 2027.
2. Manufacturing Partnership with Adair Pharma
Following an FDA inspection that raised concerns about its international manufacturer, the company accelerated a shift to US-based production by partnering with Adair Pharma, aiming to mitigate geopolitical risks and secure uninterrupted product supply.
3. Raw Material Stockpile Strategy
The company has amassed over three years’ worth of raw plant material ahead of launch to protect against supply shortages, maintain consistent production output, and support rapid scale-up once approval is granted.
4. Commercial Launch Plans and Payer Engagements
Achieve’s commercial team has conducted 40 payer touchpoints under the Affordable Care Act framework and will increase provider awareness through disease-state education and presentations at key conferences like ATS to ensure coverage and uptake post-launch.